Merendino Lauren 内部人交易：近期 SEC Form 4 交易
过去 18 个月，Merendino Lauren（CIK 1855298）在 1 家公司共报告 18 笔 SEC Form 4 内部人交易（最近一笔 2026-04-23）。
| 日期 | 公司 | 身份 | 类型 | 股数 | 市值 |
|---|---|---|---|---|---|
| 2026-04-23 | Day One Biopharmaceuticals, Inc. (DAWN) | Chief Commercial Officer | 卖出 | 60,157 | $0 |
| 2026-02-18 | Day One Biopharmaceuticals, Inc. (DAWN) | Chief Commercial Officer | 买入 | 3,162 | $0 |
| 2026-02-18 | Day One Biopharmaceuticals, Inc. (DAWN) | Chief Commercial Officer | 买入 | 3,688 | $0 |
| 2026-02-18 | Day One Biopharmaceuticals, Inc. (DAWN) | Chief Commercial Officer | 买入 | 3,687 | $0 |
| 2026-02-18 | Day One Biopharmaceuticals, Inc. (DAWN) | Chief Commercial Officer | 买入 | 4,625 | $0 |
| 2026-02-18 | Day One Biopharmaceuticals, Inc. (DAWN) | Chief Commercial Officer | 卖出 | 5,814 | $67,442 |
| 2025-11-18 | Day One Biopharmaceuticals, Inc. (DAWN) | Chief Commercial Officer | 买入 | 3,162 | $0 |
| 2025-11-18 | Day One Biopharmaceuticals, Inc. (DAWN) | Chief Commercial Officer | 买入 | 3,687 | $0 |
| 2025-11-18 | Day One Biopharmaceuticals, Inc. (DAWN) | Chief Commercial Officer | 买入 | 3,687 | $0 |
| 2025-11-18 | Day One Biopharmaceuticals, Inc. (DAWN) | Chief Commercial Officer | 卖出 | 3,726 | $33,199 |
| 2025-08-19 | Day One Biopharmaceuticals, Inc. (DAWN) | Chief Commercial Officer | 买入 | 3,162 | $0 |
| 2025-08-19 | Day One Biopharmaceuticals, Inc. (DAWN) | Chief Commercial Officer | 买入 | 3,687 | $0 |
| 2025-08-19 | Day One Biopharmaceuticals, Inc. (DAWN) | Chief Commercial Officer | 买入 | 3,687 | $0 |
| 2025-08-19 | Day One Biopharmaceuticals, Inc. (DAWN) | Chief Commercial Officer | 卖出 | 3,766 | $25,496 |
| 2025-05-19 | Day One Biopharmaceuticals, Inc. (DAWN) | Chief Commercial Officer | 买入 | 3,162 | $0 |
| 2025-05-19 | Day One Biopharmaceuticals, Inc. (DAWN) | Chief Commercial Officer | 买入 | 3,687 | $0 |
| 2025-05-19 | Day One Biopharmaceuticals, Inc. (DAWN) | Chief Commercial Officer | 买入 | 3,687 | $0 |
| 2025-05-19 | Day One Biopharmaceuticals, Inc. (DAWN) | Chief Commercial Officer | 卖出 | 3,927 | $24,583 |
来源：SEC Form 4 申报文件 · 截至 2026-04-23